Untitled Document
Besins Healthcare

Through extensive and ongoing research, innovative solutions are being developed for a safer and more comprehensive profile. Besins Healthcare global research and development is conducted out of BHR Pharma, LLC , which focuses on unmet medical needs listed below:

BHR Pharma is developing BHR-200 (transdermal estradiol gel) for the palliative treatment of advanced androgen-sensitive carcinoma of the prostate and for the treatment of the vasomotor side effects in men undergoing androgen deprivation therapy for prostate cancer. BHR-200 is a prostate cancer treatment that uses a proprietary transdermal estradiol formulation, prescribed alone or in combination with GnRH agonists.

Afimoxifene (4-hydroxytamoxifen or 4-OHT) has the potential for use in breast cancer prevention as well as a treatment for cyclic breast pain and other benign breast conditions. A multi-center, Phase 2 trial of Afimoxifene gel vs. oral tamoxifen in women with ductal carcinoma in situ of the breast will be conducted by the National Cancer Prevention Group Consortium under the coordination of the National Institutes of Health/National Cancer Institute.

BHR Pharma has formulated a topical gel of Afimoxifene , one of the most active metabolites of tamoxifen, using Enhanced Hydroalcoholic Gel Technology. The gel is directly applied to the breast for transdermal delivery to the breast tissue. In previous clinical trials, Afimoxifene gel has been shown to be biologically active in the breast tissue, while having systemic exposure in the plasma that is nine times lower than that of oral tamoxifen.

R & D